Safe Harbor Landing Pad Cell Line Jurkat T-Lymphocytes

Name: Safe Harbor Landing Pad Cell Line Jurkat T-Lymphocytes
Brand: SIGMA

human male peripheral blood (Source Disease: Acute T cell leukemia)

Synonym(e):

T-Lymphocyte Cell Line

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern

Über diesen Artikel

UNSPSC Code:

41106514

NACRES:

NA.81

Biological source:

human male peripheral blood (Source Disease: Acute T cell leukemia)

Growth mode:

Suspension

Technischer Dienst

Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.

Unterstützung erhalten

Eigenschaften

Produktname

Safe Harbor Landing Pad Cell Line Jurkat T-Lymphocytes,

biological source

human male peripheral blood (Source Disease: Acute T cell leukemia)

Quality Segment

200

form

frozen liquid (Vial of Frozen Cells)

growth mode

Suspension

technique(s)

cell culture | mammalian: suitable

shipped in

dry ice

storage temp.

−196°C

Beschreibung

General description

The STR profile of this cell line matches that of its parental cell line ATCC^® Catalog No. TIB-152. Jurkat T lymphocytes are a human, acute T cell lymphoma cell line isolated in the late 1970s from the peripheral blood of a young male patient suffering from T cell leukemia. The cells possess a pseudodiploid karyotype and have been characterized as expressing CD3 and, upon stimulation, interleukin-2.

Application

This product is a human Jurkat T-lymphocyte cell line in which a landing pad cassette has been integrated into the AAVS1 safe harbor locus using CompoZr^® Zinc Finger Nuclease technology. The mKATE2 fluorescence gene was integrated following the EF1a promoter and flanked by unique Cre-lox sites. The design of this landing pad cassette allows for easy, fast, and affordable genetic modification using Cre recombinase. mKATE2 can easily be exchanged for a payload of the user′s choice using Cre recombinase and a targeting vector with appropriate lox sites. Cells can then be sorted via fluorescence-activated cell sorting (FACS) for loss of mKATE2 expression as a surrogate for successful integration of the targeting vector. Approximately 7-10 days are required for loss of the mKATE2 signal in successfully targeted cells. See technical bulletin for detailed protocols.

Biochem/physiol Actions

These cells are a human, acute T cell lymphoma cell line isolated from the peripheral blood of a young male suffering from T cell leukemia. The cells possess a pseudodiploid karyotype, express CD3 and, upon stimulation, IL-2.

Features and Benefits

These cells contain the mKATE2 fluorescence gene flanked by unique Cre-lox sites inserted in the AAVS1 safe harbor gene. These Jurkat cells are grown in suspension with a doubling time of approximately 22 hours.